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A Novel Plasmodium falciparum Sporozoite and Liver Stage 
Antigen (SALSA) Defines Major B, T Helper, and CTL Epitopes1
Emmanuel Bottius,* Lbachir BenMohamed/ Karima Brahimi/ Hélène Gras/ 
Jean-Paul Lepers/ Lucie Raharimalala/ Masamichi Aikawa/ Jacques Meis^ 
Bas Slierendregt/ Andre Tartar/ Alan Thomas/ and Pierre Druilhe2*
In the search for subunit vaccines that are able to induce the type of sterile, protective immunity achieved by irradiated 
sporozoites, there is increasing evidence that defense mechanisms directed at the intrahepatic stage and Ags expressed at this 
stage are critical. We have initiated a systematic search for such molecules and report here the identification and partial 
characterization of a novel Plasmodium falciparum gene encoding a 70-kDa protein, expressed in both sporozoite and liver 
stages (SALSA), with a vaccine potential that stems from its antigenic features. Antigenicity and immunogenicity studies were 
conducted in individuals exposed to malaria, in immunized mice, and in chimpanzees, using a recombinant protein and two 
synthetic peptides. Results show that the SALSA nonrepetitive sequence defines 1) major B cell epitopes, as shown by a high 
prevalence of Abs to each peptide in three African areas differing in their level of endemicity; 2) Th epitopes, as demonstrated 
by lymphoproliferation and I FN-y secretion in cells from the individuals from one of the low transmission areas, as well as helper 
effect upon Ab secretion in mice; and 3) epitopes for cytolytic lymphocytes, demonstrated in immunized and sporozoite- 
challenged chimpanzees, and associated with MHC class I leukocyte Ags. The latter are of particular importance, because this 
is the only part of the malaria life cycle in which the parasite is located in a cell expressing class I Ags and because C D 8+ 
lymphocytes were found to be responsible for protection in experimental models. The Journal of Immunology, 1996, 156: 
2874-2884.
R esearch to develop a malaria pre-erythrocytic stage vac­cine siems from a very unusual and therefore striking phenomenon in the field of immunity to parasites, 
namely that the immunity resulting from the injection of irradiated 
sporozoites is a total, sterilizing resistance, allowing the vaccinee 
to fully resist challenge by large numbers of virulent parasites. 
Initially, because this state was induced by injection of sporozo­
ites, research focused primarily on sporozoite surface molecules, 
and in particular on the major circumsporozoite (CS)3 surface mol­
ecule. However, CS immunization in many formulations has al­
ways been disappointing in comparison with that obtained with 
attenuated sporozoites (1).
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There is consequently a recognized need to investigate the po­
tential of other pre-erythrocytic stage Ags. Growing evidence in­
dicates that those Ags expressed during liver stage development 
are critical. A requirement for postsporozoite developmental Ags 
was indicated when only those sporozoites injected i.v. that re­
tained the capability to transform into intrahepatic trophozoites 
were protective (2) and could remain in the liver for prolonged 
periods of time (3,4). Parallel in vivo/in vitro experiments established 
a clear-cut relationship between protection and the ability of sporo­
zoites to invade the hepatocytes (5). The destruction of these live liver 
trophozoites by primaquine treatment reversed protection (4).
Liver stages appear to be targets for more varied and more ef­
ficient defense mechanisms than sporozoites alone. Views have 
moved from a focus on Ab-dependent mechanisms directed 
against free sporozoites, prevalent 10 to 15 yr ago, to a focus on 
incorporating (based on rodent experiments) a wide range of ef­
fectors such as ADCC-like inhibition; a large number of leuko­
cyte-derived mediators, of which the cytokines IFN-y, IL-1, and 
IL-6 are the most efficient, as well as free oxygen radicals and 
nitric oxide intermediates; and direct cytolysis by lymphocytes of 
the infected hepatocytes (6). In human malaria, far less is estab­
lished regarding the effectors of immunity induced by irradiated 
sporozoites. It is known that Abs and IFN-y.have a substantial, 
although subtotal, effect against Plasmodium falciparum  (7, 8). 
Although direct evidence for CTL activity against infected hepa­
tocytes is still lacking, indirect indications were obtained from 
epidemiologic studies (9, 10).
Several years ago, as evidence for the critical role of intrahepa- 
tocytic parasite development emerged, we initiated a detailed study 
of the antigenic content of P. falciparum pre-erythrocytic stages. 
We confirmed the existence of several non-CS sporozoite surface 
molecules (11) and developed a systematic strategy to identify, 
characterize, and screen liver stage-expressed molecules (12).
Copyright © 1996 by The American Association of Immunologists 0022-1 767/96/$02.00
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Table I. Choice of discriminating seraa
Sera IFA-Sporozoite ELISA-CS
1 < 100 0.7
2 400 1.8
3 6,400 11.8
4 6,400 1.1
5 1,600 5.8
6 800 5.6
7 12,800 0.6
8 6,400 8.6
9 < 1 0 0 1.9
10 25,600 0.9
0 Results of detection of Abs directed to whole sporozoite surface molecules 
(iFA reciprocal titers) and to circumsporozoite Ag repeats (ELISA ratios to values 
from healthy controls + 3 SD). The three discriminating sera that were used to 
select non-cs (i.e., SALSA) Ag are underlined.
LSA-1 was the first to be reported (13); more recently we have 
described the sporozoite threonine- and asparagine-rich protein 
(STARP).
We report here the identification of a novel sporozoite and liver 
stage antigen (SALSA) and describe antigenicity studies in hu­
mans and iuimunogenicity studies in animals that demonstrate that 
SALSA-derived epitopes, which are not defined by a repetitive 
structure, have valuable immunologic properties that may contrib­
ute to an effective malarial vaccine.
Materials and Methods
Antibodies
Discriminating sera. Sera were selected as follows. Among subjects liv­
ing in malaria endemic areas, we had previously observed a frequent dis­
crepancy between the results from sporozoite surface labeling and recog­
nition of the CS repeats (11), suggesting the prevalence of high titers of 
Abs to non-CS surface molecules. In a series of 150 individuals, we thus 
selected sera with high Ab titer to sporozoite surface components in a 
“ wet” sporozoite immunofluorescence assay (IFA) (14), yet having low or 
no detectable Ab to CS, as measured by ELISA (Table I) and by Western 
blots (not shown). The three discriminating sera that were used to select 
non-CS, i.e., the SALSA Ag, are those underlined in Table I.
Two discriminating sera for identifying new liver stage Ags were se­
lected in a similar manner. We chose individual endemic sera that had high 
Ab titers by IFA to P. falciparum liver stages and yet were very low or 
negative when tested by ELISA on B cell epitopes containing peptides 
from the LSA-1 Ag (13, 15).
Sera directed to heterologous malaria species. To assess the species 
specificity of the new molecule, we employed four sera from Plasmodium 
vivax infections, two from Plasmodium ovale, two from Plasmodium ma- 
lariae, two from Plasmodium cynomolgii infections in man (16), one from 
Plasmodium berghei, and two from Plasmodium yoelii in mice, These sera 
were chosen because they contained significant amounts of Abs when as­
sayed by IFA on Ags (sporozoites and blood stages) from the homologous 
species. Finally, we used three mAbs identified as specific for three non-CS 
sporozoite surface Ags of P. yoelii (17).
Tranfusion malaria sera; to assess the stage specificity of SALSA, we 
also used five sera from French patients who acquired P. falciparum blood 
stage infection by an accidentally contaminated blood transfusion (18). 
These sera were collected after treatment and had IFA Ab titers to 
P. falciparum asexual blood stages ranging from 1/600 to 1/16200, 
whereas they were negative when tested on P, falciparum sporozoites and 
liver stages (as described below (Ab assays)).
Affinity-purified antibodies. Monospecific polyclonal Abs were affinity 
purified onto the recombinant proteins by serial absorption of Abs from 
eight hyperimmune human sera that had been depleted of Abs reactive with 
/3-galactosidase. The recombinant proteins, adsorbed on isopropylthioga- 
lactoside-impregnated nitrocellulose filters (BA 85, Schleicher & Schuell, 
Dassel, Germany), were incubated serially with each of the hyperimmune 
sera and washed extensively. Abs were eluted at pH 2.5 in glycine buffer, 
neutralized, and concentrated using a Minicon apparatus (Amicon Corp., 
Beverley, MA).
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Anti-peptide Abs were prepared by affinity purification from human 
sera on ELISA plates coated with each of the two synthetic peptides de­
rived from the SALSA Ag according to the technique of Brahimi ct al. 
(19). In this case, single sera chosen on the basis of their ELISA titer to the 
corresponding peptides were used.
DNA techniques
Screening o f a genomic DNA library. Three of the discriminating sera 
shown in Table I, and two others that were positive on LS and negative on 
LSA-1, were employed to screen a subset of 120 P, falciparum genomic 
DNA clones. These were formerly identified as encoding mainly for pre- 
erythrocytic stage Ags (13); they were spotted onto nitrocellulose discs 
impregnated with isopropylthiogalactoside, as described above, and re­
acted with Abs. Following washings, the reaction was revealed with anti­
human IgG peroxidase-labeled second Abs (Biosys, Compiegne, France; 
used at 1/500 dilution).
To determine the relationship between SALSA-DG671 and a series of 
other pre-erythrocytic stages T e c o m b in a n t c lo n e s ,  the 32P-labeled DG671 
DNA insert was hybridized in 6X SSC buffer at 65°C overnight with 
DNAs (transferred to a Hybond N membrane, Amersham, Buckingham­
shire, U.K.) from the above subset o f 120 clones encoding stage-specific 
pre-erythrocytic Ags (13, 12); the membranes were then autoradiographed. 
Sequence analysis. AgtU -f-DG671 DNA was prepared from a liquid 
phage lysate and digested by EcoJU., and the gel-purified £coRI insert was 
subcloned into pUC18, The clone pUC18-HDG671 obtained was se­
quenced from both stands using the dideoxynucleotide chain termination 
method. The sequence data were obtained from P. falciparum clone T9/96. 
PCR studies. The DNA from 23 P. falciparum  lines and isolates (NF54, 
Palo Alto cultured strains, 5 isolates from Thailand, and 16 from the village 
of Dielmo, Senegal, West Africa) were prepared by phenol-chloroform 
extraction (20) and amplified by PCR using the oligonuleotides indicated in 
Figure 1. The PCR was performed for 40 cycles with the following se­
quence: 94°C for 1 min, 50°C for 1 min, 72°C for 1 min, and thereafter 
75°C foT 5 min, using Taq polymerase (Cetus Corp., Emoryville, CA) in a 
Hybaid thermal reactor. The amplified products were electrophoresed in 
4% Nusieve-agarose-genetic technology grade gel and examined under UV 
light. These were transferred to nitrocellulose and probed with 32P-labeIed 
DG671.
ForRT-PCR, NF54 sporozoite RNA was prepared as described (21) and 
enriched using a Micro-FastTrack mRNA isolation kit according to the 
manufacturer’s instructions (Invitrogen, San Diego). RT-PCR was per­
formed from 1.5 ju-g of mRNA using the Superscript reverse transcriptase 
(Life Technologies, Gaithersburg, MD) and Taq polymerase (Amersham) 
with the same oligonucleotides and the same amplification program as 
described above.
Study areas and subjects
The three areas of field study have been previously described in detail (15). 
The individuals studied ranged in age from 1 to 75 yr. The village of Podor 
is located in the Northern part of Senegal, an almost desert-like part of the 
Sahel. The transmission of malaria by mosquitoes is seasonal, as in the 
other two areas, and there was estimated to be an average one infective bite 
per person per year (22), with relatively large yearly variations (one to five) 
depending on the amount of rainfall. Donse is in the savannah part of 
Burkina Faso, 50 km north o f Ouagadougou. Malaria transmission reaches 
100 infective bites/individual/year (14), which is high, although average by 
African standards. Ankazobe, where the population is mainly of Asian 
origin, is one of the rare villages in the highlands of Madagascar where 
transmission (10 infective bites/individual/year on average) has remained 
uninterrupted over the past 20 yr. There are large variations from one 
household to another, due to greater differences in the building materials 
employed as compared with the very homogeneous habitat of the other two 
villages, and depending also on the distance from the main breeding 
site, which is the rice fields. For T cell studies, after informed consent 
was obtained from the donors or their parents, blood was collected on 
Liquemine (Roche, Basel, Switzerland), a preservative-free heparin, 
and PBMC were processed in our laboratory in Antananarivo, M ada­
gascar within 4 to 6 h following sampling.
Ab assays
Immunofluorescence and immuno electron microscopy o f sporozoites and 
liver stages. IFA on whole sporozoite surface Ags were performed using 
wet sporozoites, NF54 strain, and sporozoites obtained after feeding 
Anopheles dims on gametocytes from four Thai patients (as described in 
Ref. 14) and expressed as the reciprocal of the last positive serum dilution. 
P. vivax, P. yoelii, and P. berghei sporozoites were produced in our lab­
oratory by feeding Anopheles stephensi mosquitoes on patient gametocytes
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well in round-bottom 96-weII microtiter culture dishes (Nunc, Roskilde, 
Denmark) filled with 200 ¡A of RPMI medium supplemented with 10% 
human AB serum, 3.7 g of sodium bicarbonate, 2 mM glutamine, 1 % 
sodium pyruvate, and 10 mM HEPES per liter. The peptides were added at 
10-/Ag/ml concentrations in quadruplicate wells. Control wells included no 
Ag, the lectin leukoagglutinin, and purified protein derivatives, both at 10 
jutg/ml. All plates were incubated for 6 days at 37°C in 5% C 02 air mixture; 
on day 6, 100 ¿d of cell-free medium was removed for IFN-y assay and 
replaced with 100 fx\ of fresh medium containig 1 /iCi of [3H]TdR. Incor­
poration was counted in a liquid scintillation spectrophotometer from cells 
collected on day 7. Stimulation indices (SI) were calculated as the ratio of 
the geometric mean cpm in quadruplicate test wells to the geometric mean 
of quadruplicate control wells (i.e., without Ag). A proliferation was con­
sidered positive when the SI was >2, with a A cpm (difference between 
signal and background values) >  1000 cpm,
IFN-y assay. The IFN-y concentration in pooled supematants from the 
quadruplicate wells was assessed by a two-site capture ELISA performed 
in duplicate using two anti-human IFN-y (mAbs were kindly given by Mrs. 
Cousin, Roussel Uclaf, Paris). Wells were coated for 48 h at 4°C with 50 
fi 1 of the anti-IFN-y mAb RU 40.2 at 5 fig/ml in PBS and further incubated 
with BSA (3%) in PBS as blocking buffer. Undiluted supernatant from 
Ag-stimulated T cells (50 fxl/well) was added for 16 h at room temperature, 
and the wells were then washed three times with PBS-Tween, 0.1%. A 
second anti-IFN-y mAb, RU 308.7, coupled to peroxidase was added in the 
wells at a 0.8 jtig/ml concentration and left for 24 h at 4°C. The wells were 
washed three times and the activity was revealed after a 15-min incubation 
at room temperature with 100 /¿I of reaction substrate (OPD 1 mg/ml, H20 2 
30%: 1 jul in citrate buffer, pH 5.0), and the absorbance was read at 450 nm 
on a Dynatech reader. The IFN-y content of supematants was calculated 
from standard curves performed with the same culture medium, containing 
known amounts of IFN-y (1000-0,1 IU/ml), included in each plate. 
Cytotoxic T lymphocyte assays. CTL assays were performed using PBLs 
from the SALSA-immunized chimpanzees, Bart and Socrates, and four 
control chimpanzees (Dirk, Ruud, Cor, and Peer), PBLs were separated on 
Ficoli-Hypaque, resuspended in RPMI 1640 supplemented with 10% hu­
man AB serum, and restimulated by incubation of cells with either 
SALSA-1 or SALSA-2 peptides (10 jug/ml of each peptide) in 25-cm2 
Falcon flasks. IL-2 (rIL-2, Genzyme, Cambridge, MA) was added (20 IU/ 
ml) at 72 h, and assays were performed after 7 days of culture at 37°C in 
7.5% C 0 2/air.
The 51Cr release assays were conducted using peptide-pulsed cells, ei­
ther autologous EBV-transformed B (EBV-B) lymphocytes or PHA blasts, 
as target cells. The PHA blasts were generated by stimulating 106 autolo­
gous PBMC with 0.5 ¡jlg/ml of l-PHA for 3 days. The target cells were 
incubated overnighL at 37°C in the presence or absence of 20 ¡xgfml of 
individual peptide (SALSA-1, SALSA-2, or a control peptide, MSP-3b 
from a blood stage Ag (28)) and 3 ju,g/ml of human /32-microglobulin 
(Sigma Chemical Co., St. Louis, MO) in RPMI medium (Life Technolo­
gies) supplemented by 20% human AB serum. After labeling with 150 /¿Ci 
of Na251C r04 (ICN Biomedical Inc., Irvine, CA) for 60 min at 37°C, the 
cells were washed three limes, and 5 to 10 X 103 target cells were added 
to duplicate wells in 96-well round-bottom microtiter plates (Coming 
Glass, Corning, NY). Effector cells were added at various E:T cell ratios, 
and the plates were incubated for 5 h at 37°C in 7.5% C 02/air. Supernatant 
(100 fil) was removed from each well and quantitated for 51Cr using a 
gamma counter. The MSP3-b peptide, which was used as control, corre­
sponds to the sequence AKEASSYDYILGWEFGGGVPEHKKEEN.
To assess class I or class II presentation of Ag, mAbs, either anti- 
HLA-DR (5 /ig/ml of Mab L-243) (29), or anti HLA-A-B-C (1/1000 di­
lution of ascite supernatant of Mab W6/32, a dilution found to inhibit class 
I-restricted cytotoxic T cell responses) (30), or an irrelevant IgG2a Ab used 
as control, were added to 106 target cells for 1 h at 4°C and remained 
present throughout the 5-h CTL assay.
The percentage of specific lysis was determined as follows: % lysis =  
(experimental release — spontaneous release)/(total release — spontaneous 
release) X 100.
Immunization of animals
Mice. To investigate Th activity, two groups of five outbred Swiss albino 
mice (Charles River, St. Aubin les Elbeuf, France) were immunized on day 
0^by s.c. injection of either 50 fig of SALSA-1 peptide emulsified in CFA, 
or for controls, saline in CFA. They were boosted 40 days later by s,c. 
injection of 50 jig of the recombinant j3-galactosidase-SALSA protein 
(clone DG671), containing both SALSA-1 and -2 peptide sequences), in 
IFA. Sera taken on days 0,40, and 60 were studied in ELISA assays toward 
peptides SALSA-1 and -2, as described above, to investigate the occur­
rence of a secondary Ab response to peptide SALSA-2, thus indicating help
provided by SALSA-1 priming. In further experiments, we also investi­
gated the immunogenicity of either of the two peptides (two injections of 
50 fig at 15-day intervals in CFA/IFA), or the recombinant DG671 alone 
(three injections of 50 fig at 15-day intervals using CFA/IFA, Titermax, or 
saponin as adjuvants).
Chimpanzees. Socially housed, captive bred, male chimpanzees (Pan trog­
lodytes), 10 to 15 yr old, were used under veterinary supervision. As part 
of a series of experiments, chimpanzees Bart and Socrates received three 
s.c. injections of 50 fig of purified /3-galactosidase-SALSA recombinant 
protein represented in clone DG671 adsorbed on alum and were challenged 
by i.v. inoculation of 28 million sporozoites from the NF54 strain. Boosting 
was performed 18 mo later by s.c. injection of GST-671 recombinant pro­
tein emulsified in Montanide ISA 51 as adjuvant. The cells studied in 
lymphoproliferative and CTL assays were taken either before, or 1,3, 8, 9, 
12, 18, and 20 mo after challenge and 30 and 65 days after the boost. Cells 
from chimpanzees Cor and Peer, who received three injections of control 
Ag consisting of the carrier molecule /3-galactosidase, and from Dirk and 
Ruud, who were immunized by other LS molecules (all received the same 
28 million sporozoite challenge at the same time), were used as controls. 
Preliminary data from challenge of the SALSA-immunized chimpanzees 
and from inhibition of sporozoite invasion assays performed with sera from 
immunized chimpanzees already suggest that SALSA may be involved in 
protective responses. The results of this and other challenges will be re­
ported separately (A. Thomas et al., manuscript in preparation).
Results
Identification of a novel sporozoite surface molecule
To select non-CS sporozoite surface Ags, we used an approach 
similar in principle to that formerly used to detect clones express­
ing a LSA (13, 12), i.e., the screening of a P. falciparum expres­
sion library with polyclonal human Abs of restricted specificity. 
Three sera that had low or undectable levels of anti-CS protein, 
and yet were strongly positive in a “ wet”  sporozoite IFA (Table 
I), and two sera that were negative for LSA-1 reactivity, and yet 
were strongly reactive with liver stage by IFA, were used in this 
selective screen, From a group of 120 P. falciparum genomic DNA 
clones encoding predominantly pre-erythrocytic Ags, these sera 
facilitated the selection of 12 candidate clones. Stage specificity 
was assessed by sporozoite, liver stage, and blood stage IFA with 
human Abs that had been affinity purified on the clones. Due to the 
reported genetic restriction of CS epitopes for Th cells and the 
consequent low prevalence of Abs to CS among subjects from 
highly endemic areas (11), we wished to select only those clones 
expressing epitopes that were more consistently recognized by ma­
laria-exposed individuals. A complementary set of 10 sera from 
both low and high endemicity areas was therefore used to study the 
prevalence of specific Ab response in Western blots against re-
V
combinant products. From this screening, one consistently well 
recognized clone, DG671, was selected and submitted to further 
studies.
Affinity-purified human Abs on DG671 were found to be 
strongly reactive by IFA with the surface of sporozoites from 
NF54 strain (see below) showing an evenly distributed labeling 
over the entire surface, which was also detectable in four addi­
tional sporozoite isolates from Thailand (not shownj.
Sequence analysis of the DG671 clone showed that the 249-base 
pair fragment contains only one open reading frame, encoding an 
83-aa nonrepeat stretch (Fig. 1A). PCR amplification of DNA from 
this region in 5 Asian and 2 African culture-adapted strains, and in 
16 isolates from Senegal, showed no size polymorphism (e.g., Fig. 
1C). The SALSA polypeptide is rich in glutamic acid (17%), ly­
sine (19%), and serine (13%), but contains no methionine or cys­
teine and tyrosine. Although, in contrast with other Plasmodium 
proteins, SALSA does not contain repeated sequences, a typical 
pattern consisting of two acidic residues (Asp or Glu) clustured 
between two lysine residues is found five times (KKDEK, KD 
DVK, KEEKK, KDDGK, KVLEK). No homology with known P.
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FIGURE 5. Th activity of SALSA-1 peptide. Outbred Swiss mice 
primed with peptide SALSA-1 (A) or saline (B) were boosted with the 
recombinant SALSA protein DG671 (containing both SALSA-1 and -2 
peptide sequences). Ab responses were measured by ELISA against 
SALSA-1 (vertical stripes) and SALSA-2 (hatched columns) peptides. 
The high response to SALSA-2 at day 60 is suggestive of a secondary 
type of response, indicating Th activity provided by SALSA-1.
(e.g., SI of 45 and 15, respectively, in the Bart sample taken 8 mo 
after challenge were representative of the values seen throughout). 
In contrast, both assays were negative in two control animals im­
munized with the /3-galactosidase carrier molecule alone and in 
two chimpanzees immunized with other LSAs before and after the 
challenge.
For CTL assays, PBLs from Bart were taken 9 mo after chal­
lenge, and cell lines were established by in vitro stimulation with 
SALSA» 1 and 2 peptides for 7 days before performing the assay. 
A potent, peptide-specific cytolytic effect was detected for 
SALSA-2- and, to a lesser extent, for SALSA-1-stimulated cells 
against autologous PHA blasts (Fig. 6, A and B), The lysis was 
peptide specific, as negative results were obtained with control 
peptide-pulsed target cells (Fig. 6, C and D), and with SALSA-2- 
specific effector cells towards SALSA-l-pulsed targets (not shown 
in the figure). In the cells from the other immunized chimpanzee, 
Socrates, a similar cytolytic activity towards SALSA-l-pulsed 
cells was observed (Fig. 6F), whereas no CTL activity to SALSA 
peptides was detected in material taken at the same time points 
from the four control animals, despite the fact that they had re­
ceived a similar sporozoite challenge.
In samples taken from Bart 18 and 20 mo after challenge, 
CTL activity was still detectable (specific lysis 60-30%  in the two 
succesive assays). The animal was then immunized again with 
SALSA material, and in samples taken 30 days after this boost the 
CTL activity was restored to the high initial levels (Fig. 6E). This 
result was confirmed in cells from a second sample drawn at 65 
days (not shown). In both cases, responses were clearly shown to 
be class I-res trie ted, as in the presence of Mab W6/32 the CTL 
activity specific of each peptide was totally abolished (Fig. 6E, 
black columns), whereas this was not the case when using anti- 
HLA-DR Abs (not shown).
Discussion
To date, attempts to develop a malaria vaccine have primarily fo­
cused on the asexual blood stage and on CS, the major sporozoite 
surface Ag, whereas the liver stage of parasite development has 
attracted relatively little interest. Through rodent malaria models, 
it has recently become clear that LS axe susceptible to attack by a 
variety of immune effectors, including the direct and indirect ef­
fects of Ab and T cells. The main difficulties in exploiting this 
progress for the development of a pre-erythrocytic stage vaccine 
are twofold: 1) the malaria pre-erythrocytic stage (MPES) anti-
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FIGURE 6. Identification of CTL epitopes in SALSA-1 and -2 pep­
tides. A through D, Specific release at various E:T ratios with Bart cells 
stimulated by SALSA-2 peptide, directed toward SALSA-2-pulsed au­
tologous PHA blasts (A) compared with (O  SALSA-2 effector cells with 
autologous cells pulsed with an irrelevant 27-aa peptide derived from 
the P. falciparum blood stage Ag MSP3. In a similar fashion, specific 
CTL response in the chimpanzee Bart was also evident against 
SALSA-1 (B) in comparison with the control peptide (D). Both 
SALSA-1 and -2 peptide responses are MHC class I restricted (E). CTL 
responses to SALSA-1 peptide obtained in cells from the chimpanzee 
Socrates (F) (hatched columns indicate SALSA-l-pulsed targets; clear 
columns indicate control, LSA-1-pulsed targets) (shown is a single E:T 
of 20:1 and two peptide concentrations for pulsing target cells, 100 
and 10 julM). All results are expressed in percentage of specific release.
genic repertoire remains largely unknown; and 2) protective mech­
anisms vary widely between the rodent/Plasmodium combinations 
used. None of the combinations is considered to be more relevant 
to the human situation than the others (6, 34). Thus it is still not 
clear which molecule(s) inducing which mechanism(s) has the 
most promise against P. falciparum (or P. vivax) MPES in hu­
mans. The novel MPES molecule that we identify here is a sporo­
zoite surface and liver stage Ag that is a potential target for several 
protective defense mechanisms, particularly in view of its ability to 
induce B, Th, and CTL responses that may act successively on 
sporozoites and LS.
We have undertaken molecular characterization sufficient to 
demonstrate that SALSA does not represent any of the P. falcipa­
rum genes reported to date. It does not contain any repeated motif. 
The region of the SALSA gene we have characterized was chosen, 
apart from its stage expression, based on Ab detection, yet was 
found to contain valuable T cell determinants. The prevalence of 
Ab in a limited selective panel of sera was a complementary initial
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selection criterion, and further Ab studies confirmed that the mol­
ecule contains potent B cell epitopes. Indeed, the proportion of 
individuals carrying Abs directed to each peptide is relatively high 
in all three transmission areas studied and in each age group. The 
prevalence and titer of Abs were consistently higher to SALSA-2 
than to SALSA-1 in the three areas, indicating that the former 
peptide defines a major B cell epitope.
One of the remarkable features of those SALSA B cell deter­
minants is that, in contrast to many of the P. falciparum proteins 
characterized to date, they are not defined by repeats. Indeed, in 
most molecules, such as MSA1, MSA2, GLURP, etc., from blood 
stages, or CS, LSA-1, or STARP from pre-erythrocytic stages, the 
repeat region is the main target of Abs relative to nonrepeated 
regions (15, 35). Moreover, long series of repeats can bind more 
Ao molecules than single, nonrepeated epitopes. Nevertheless, our 
sti.dy shows that the prevalence and titer of Abs to SALSA ex­
cel ds that directed to CS repeats, a recognized dominant epitope 
on sporozoites, to RESA repeats, or to STARP repeats (V. Pas- 
que.to, D. A. Fidock, E. Badell, W. Eling, H. Gras-Masse, and 
P. Druilhe, manuscript in preparation), are similar to the dominant 
repeated epitope of LSA-1 in the same study population (15) and 
are well above the prevalences of Abs directed to nonrepeated 
regions of CS (11) or LSA-1 (15).
For the analysis of B cell responses, the two areas of low malaria 
transmission (by African standards) of Podor and Ankazobe pro­
vide a more discriminative tool than the “ standard” savanna hy- 
perendemic area of Donse. Results for these two areas, particularly 
in young children, reveal the remarkable immunogenicity of 
SALSA, when considering that individuals receive about 1 to 10 
infective bites per year and that each inoculation is made of about 
10 sporozoites only, of which about one-half can be expected to 
transform into liver schizonts (23, 36), Nevertheless, more than 
one-half of the younger children in these two areas have detectable 
Abs to SALSA peptides. This is consistent with the identification 
of Th cell epitopes in the same molecule. A similarly high prev­
alence of Ab responders to SALSA-2, more than to SALSA-1, was 
also observed in other regions of Africa, reaching 85% of all age 
groups in the Senegalese village of Dielmo (J. L. Sarthou et al., 
manuscript in preparation) and above 90% in adults living in Kilifi 
in Kenya (J. Sherwood et al., unpublished data).
From a functional point of view, Abs directed to sporozoite surface 
molecules, such as CS and STARP, have been shown to reduce in a 
dose-dependent manner the rate of sporozoite invasion into hepato- 
cytes (7) (V. Pasquetto, D. A. Fidock, E. Badell, W. Eling, H. Gras- 
Masse, and P. Druilhe, manuscript in preparation). The identification 
of SALSA extends the range of Ags that can be targeted by Abs at the 
sporozoite level. Preliminary studies in our laboratory indicate that 
anti-SALSA peptide Abs can significantly reduce sporozoite invasion, 
thus confirming the surface-accessible location of the molecule 
(V. Pasquetto et al., manuscript in preparation).
SALSA being expressed on sporozoites, and during liver stage 
development, offers possibilities for both humoral and cellular im­
mune targeting. In view of the potential role for CD8+ lytic tar­
geting of SALSA, and the frequent requirement for T cell help in 
the induction of such responses, we investigated T cell prolifera­
tive responses to the SALSA peptides in humans, chimpanzees, 
and mice.
The induction of Th cell activity by SALSA-1 peptide was 
clearly indicated when boosting with the recombinant molecule 
induced strong anti-SALSA-2 responses. The presence of deter­
minants for human T cells was shown by the induction of specific 
proliferative responses and IFN-y secretion in individuals from the 
endemic area o f Ankazobe, but not in control non-malaria ex- 
posed-donors. Both regions of the molecule predicted to adopt an
a-helicai conformation were able to stimulate T cells, as demon­
strated previously for similarly conformed regions of LSA-1 (15). 
The prevalence of responders to SALSA-1 and SALSA-2 peptides 
was of the same order of magnitude as that observed to the Th2-R 
peptide from CS in the same area, or in previous studies in other 
areas (37), and close to those observed for various LSA-1 peptides 
in the same population (15). The dissociation of responses to the 
peptides confirms that they are not cross-reactive and may reflect 
individual class II ability to associate with the T cell determinants, 
thus suggesting that they may act in a complementary manner in 
distinct individuals. These results are in general agreement with 
other T cell studies with SALSA peptides performed in the high 
transmission areas o f Dielmo (J. L. Sarthou et aL, manuscript in 
preparation) and of Djoumouna in the Congo (Ph. Brasseur et a l, 
manuscript in preparation) where high to very high prevalences 
were found. Although the proportion of responders is influenced 
by a large number of factors and may vary greatly over time in 
successive studies o f the same individuals (38), this suggests that 
the relatively low prevalence seen in Ankazobe is more likely re­
lated to the low level o f transmission than to a genetic restriction 
of responses to the peptides. A potential polymorphism of T cell 
determinants in the SALSA sequence of isolates from Madagascar 
or a MHC class II restriction of CD4+ responses from the popu­
lation of Madagascar (mainly of Asian origin) are alternative hy­
potheses, which will need to be addressed by further studies.
Of particular importance for MPES Ags is the higher prevalence 
of individuals responding to both peptides by IFN-y secretion, 
which is the most potent of the cytokines thus far reported to block 
the intrahepatic development of rodent (3 9 -4 1 ), primate (42), and 
human P. falciparum  malaria (8) and is involved in defenses in­
duced by irradiated sporozoites (40). IFN-y responses did not par­
allel proliferative responses, as has been previously found with 
other molecules (15, 38, 43). Even though the DG671 insert rep­
resents only a small part of the SALSA protein, it is remarkable 
that more than 50% of the individuals studied responded to it by 
either proliferation or IFN-y production.
Our studies in immunized chimpanzees also show that SALSA  
can 1) elicit and 2) be a target for CTL lymphocytes. This result is 
particularly significant following recent data obtained in experi­
mental malaria, as well as naturally exposed human populations, 
pointing to CTL activity as a most critical defense against LS. 
Since the initial observation that ^-suppressed mice can be effec­
tively protected by immunization with irradiated sporozoites (44), 
there has been increasing evidence in favor of a major role of T 
cells, particularly of the CD8+ subset(40, 45-48).
In individuals of diverse MHC haplotypes protected by irradi­
ated sporozoites, it is clear that CTLs must be directed to a range 
of epitopes from various LS-expressed molecules. The identifica­
tion of two regions of the SALSA molecule bearing epitopes tar­
geted by CTL cells expands the range of potential epitopes for this 
critical defense mechanism. CTL activity was detected in a con­
sistent manner in successive samples, and although the level of 
lysis was variable over time, it was found to be peptide specific, 
genetically restricted, and class I dependent.
In view of the complex set of immunization and challenges in 
the chimpanzees studied, the induction pathway for these cells is 
not clear. Immunization by soluble molecules is not generally 
thought to allow Ag presentation by the endogeneous pathway 
such that association with class I molecules occurs. The ability of 
SALSA to induce Th cells and the critical role of Th in all types 
of B cell- and T cell-dependent responses leads us to believe that 
the major CD8+ CTL expansion occurred as a secondary type of 
response at the time of parasite challenge. The long-term persis­
tence of circulating CTLs is in keeping with this hypothesis, given
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that Th cells would be expected to play a role in the sustained 
production o f both Ab and CD8H~ T cells specific for the Ag.
In conclusion, the identification of the SALSA protein confirms 
the existence of additional Ags on the surface o f sporozoites and 
provides further information on the antigenic content of P. falcip­
arum liver stages. Preliminary data from immunized chimpanzees 
point to a protective role for SALSA, suggesting that we have 
identified an additional vaccine candidate for pre-erythrocytic 
stage immunization. SALSA has attractive antigenic features, in­
cluding 1) a high frequency of B and T cell responders in indi­
viduals with various genetic background and 2) the presence o f  
epitopes for both Th and T cytotoxic cells within the limited re­
gions studied. As well as the high prevalence o f responders, the 
detection of gene fragments o f similar size in over 20 isolates 
suggests that the gene is well conserved among P. falciparum iso­
lates. SALSA expression at two successive stages of parasite de­
velopment may allow for a wider array of immune effectors to act 
against a single parasite product (for example invasion-inhibition 
of sporozoites by Abs, opsonization by macrophages, Ab-depen- 
dent cellular cytotoxicity, lymphocyte cytotoxicity on infected 
liver cells, and IFN-y-mediated blockade of LS development). The 
presence o f epitopes that are potent stimulators o f T cell activities 
is a critical feature in favor of this newly identified Ag.
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